Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014-2015)
Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1835
Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing Bone and Joint Infections in USA and European Hospitals (2011-2015)
Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing Bone and Joint Infections in USA and European Hospitals (2011-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1834
Next Generation Sequencing for Genomic Analysis of Cfr(B)-producing Enterococcus faecium Causing Infections in a New Orleans Medical Center
Next Generation Sequencing for Genomic Analysis of Cfr(B)-producing Enterococcus faecium Causing Infections in a New Orleans Medical Center, Lead author: Deshpande L, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1408
Evaluation of the In Vitro Activity of Ceftaroline Tested against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015)
Evaluation of the In Vitro Activity of Ceftaroline Tested against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1846
Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates
Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1625
Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015
Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015, Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1831
Ceftazidime-Avibactam Activity when Tested against Gram-negative Bacteria Isolated from Patients with Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015)
Ceftazidime-Avibactam Activity when Tested against Gram-negative Bacteria Isolated from Patients with Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1837
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested against Gram-Negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015)
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested against Gram-Negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 703
Antimicrobial Susceptibility of KPC-Producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015)
Antimicrobial Susceptibility of KPC-Producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015), Lead author: Castanheira M, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1850
Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources
Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1824
Activity of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates
Activity of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1823
Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013)
Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 786
In Vitro Antibacterial Activity of WCK 5999: A New Carbapenem/β-lactamase Inhibitor Combination against ESBL-Phenotype and Carbapenemase Producing Enterobacteriaceae from a Worldwide Surveillance Program (2015)
In Vitro Antibacterial Activity of WCK 5999: A New Carbapenem/β-lactamase Inhibitor Combination against ESBL-Phenotype and Carbapenemase Producing Enterobacteriaceae from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-425
Activity of the New Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates Producing Oxacillinases(OXAs)
Activity of the New Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates Producing Oxacillinases (OXAs), Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-422
In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae
In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-421
In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015)
In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-476
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-447
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Antimicrobial Resistant Gram-negative Bacilli
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Antimicrobial Resistant Gram-negative Bacilli, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-446
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Enterobacteriaceae Clinical Isolates Collected Worldwide (2015)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Enterobacteriaceae Clinical Isolates Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-445
Antimicrobial Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter spp. Collected Worldwide (2015)
Antimicrobial Activity of WCK 5222 (Cefepime-Zidebactam) Tested against Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter spp. Collected Worldwide (2015), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-478
WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases
WCK 5222 (Cefepime-Zidebactam) In Vitro Time-kill Studies against Pseudomonas aeruginosa and Acinetobacter baumannii Isolates with Characterized β-lactamases, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-477
In Vitro Activity of Lactone Ketolide WCK 4873 When Tested Against Contemporary Community-Acquired Bacterial Pneumonia Pathogens from a Global Surveillance Program
In Vitro Activity of Lactone Ketolide WCK 4873 When Tested Against Contemporary Community-Acquired Bacterial Pneumonia Pathogens from a Global Surveillance Program, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-476
In Vitro Activity of WCK 4873 (Nafithromycin) against Resistant Subsets of Streptococcus pneumoniae From a Global Surveillance Program (2014)
In Vitro Activity of WCK 4873 (Nafithromycin) against Resistant Subsets of Streptococcus pneumoniae From a Global Surveillance Program (2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-455
WCK 4282 (High-Dose Cefepime-Tazobactam) Disk Diffusion Quality Control Ranges Using a Multi-laboratory Study Design
WCK 4282 (High-Dose Cefepime-Tazobactam) Disk Diffusion Quality Control Ranges Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-018
Enhanced Activity of WCK 4282 (Cefepime-Tazobactam) Against KPC-Producing Enterobacteriaceae Collected Worldwide When Tested in Physiological Conditions
Enhanced Activity of WCK 4282 (Cefepime-Tazobactam) Against KPC-Producing Enterobacteriaceae Collected Worldwide When Tested in Physiological Conditions, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-427
In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program
In Vitro Activity of WCK 771, a Benzoquinolizine Fluoroquinolone (Levonadifloxacin) when Tested Against Contemporary Gram-Positive and -Negative Bacteria from a Global Surveillance Program, Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-456
Activity of Telavancin Against a Global Collection of Staphylococcus aureus Causing Bacteremia (2011-2014)
Activity of Telavancin Against a Global Collection of Staphylococcus aureus Causing Bacteremia (2011-2014), Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-335
Activity of TelavancinAgainst Gram-positive Pathogens Isolated from Bone and Joint Infections in North American, Latin American, European and Asia-Pacific Nations
Activity of TelavancinAgainst Gram-positive Pathogens Isolated from Bone and Joint Infections in North American, Latin American, European and Asia-Pacific Nations, Lead author: Jones RN, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-445
Synergistic Effect of Gram-positive Agents Tested in Combination with a New Polymyxin Derivative (SPR741) against Multidrug-resistant Gram-negative Pathogens
Synergistic Effect of Gram-positive Agents Tested in Combination with a New Polymyxin Derivative (SPR741) against Multidrug-resistant Gram-negative Pathogens, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-490
S-649266 MIC Quality Control Ranges in Iron-depleted cation-adjusted Mueller-Hinton Broth Using a Multi-laboratory Study Design
S-649266 MIC Quality Control Ranges in Iron-depleted cation-adjusted Mueller-Hinton Broth Using a Multi-laboratory Study Design, Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-028
Oritavancin Longitudinal In Vitro Activity Against Gram-positive Organisms from USA Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
Oritavancin Longitudinal In Vitro Activity Against Gram-positive Organisms from USA Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010-2014, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-345
Meropenem-vaborbactam (MER-VAB) Tested Against Contemporary Enterobacteriaceae Isolates from USA Hospitals
Meropenem-vaborbactam (MER-VAB) Tested Against Contemporary Enterobacteriaceae Isolates from USA Hospitals, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-452
Evolving Linezolid Resistance Mechanisms in a Worldwide Collection of Enterococcal Clinical Isolates: Results from the SENTRY Antimicrobial Surveillance Program
Evolving Linezolid Resistance Mechanisms in a Worldwide Collection of Enterococcal Clinical Isolates: Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Saturday-332
Gepotidacin (GSK2140944) In Vitro Activity Against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME Tests)
Gepotidacin (GSK2140944) In Vitro Activity Against Neisseria gonorrhoeae (MIC/MBC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-461
Gepotidacin (GSK2140944) In Vitro Activity Against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME Tests)
Gepotidacin (GSK2140944) In Vitro Activity Against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME Tests), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-460
In vitro Activity of Delafloxacin When Tested Against Contemporary Bacterial Pathogens from the USA (2014)
In vitro Activity of Delafloxacin When Tested Against Contemporary Bacterial Pathogens
from the USA (2014), Lead author: Flamm RK, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-457
Activity of Ceftazidime-Avibactam Tested against Clinical Isolates of Antimicrobial Resistant Pseudomonas aeruginosa from United States Medical Centers (2012-2014)
Activity of Ceftazidime-Avibactam Tested against Clinical Isolates of Antimicrobial Resistant Pseudomonas aeruginosa from United States Medical Centers (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-436
Ceftazidime-Avibactam Antimicrobial Activity When Tested against Gram-negative Bacteria Isolated from Intensive Care Unit (ICU) Patients with Pneumonia (2012-2014)
Ceftazidime-Avibactam Antimicrobial Activity When Tested against Gram-negative Bacteria Isolated from Intensive Care Unit (ICU) Patients with Pneumonia (2012-2014). Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-434
Ceftazidime-Avibactam Activity Tested against Eleven Enterobacteriaceae Species Producing KPC Enzymes
Ceftazidime-Avibactam Activity Tested against Eleven Enterobacteriaceae Species Producing KPC Enzymes, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-451
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014)
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014), Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-435
Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure
Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. by Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN and Bradley JS. published in Pediatr. Infect. Dis. J. 2016; 35 (7): 813-815
Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014)
Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design
WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design, Lead author: Ross JE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
In Vitro Activity of Plazomicin tested against Contemporary Clinical Isolates Collected in Asia-Pacific, Europe and Latin America
In Vitro Activity of Plazomicin tested against Contemporary Clinical Isolates Collected in Asia-Pacific, Europe and Latin America, Lead author: Castanheira M, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014)
Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014)
Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Antimicrobial Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Tested against Gram-negative Organisms from Medical Centers Located in Europe and the Asia-Pacific Region
Antimicrobial Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Tested against Gram-negative Organisms from Medical Centers Located in Europe and the Asia-Pacific Region, Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014)
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014)
WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015)
Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
